AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.

Explore the significant impact of obesity on multiple sclerosis (MS) progression, including increased symptoms, disability, and comorbidities. Learn how to manage weight effectively with professional ...

Research shows that Blacks may develop multiple sclerosis more often than previously thought. Additionally, the symptoms of ...

Researchers at the University Health Network and University of Toronto led the discovery of a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients ...

The progression of relapsing-onset multiple sclerosis (MS) and its associated disability may be slowing, results from a large population-based study suggest. In an evaluation of more than 7000 ...

When Derek Stefureac was diagnosed with multiple sclerosis, a chronic disease that affects the central nervous system, he was a smoker who never exercised. Everything changed when he had an "attack" ...

PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...

Increases in sGFAP during BCDT are linked to disability progression in MS, independent of relapse activity. sGFAP is a stronger predictor of disease progression than sNfL, reflecting different ...

Machine learning can help predict whether people newly diagnosed with MS will experience disability worsening that occurs ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. An oral brain-penetrant therapeutic delayed the onset of ...